ArticleMetabolomics : Official journal of the Metabolomic Society2026
Integration of metabolomics and machine learning algorithm for discovery of early diagnostic biomarkers of osteoporosis.
Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOsteoporosis (OP) is a prevalent metabolic bone disorder and a major public health concern characterized by reduced bone mass and bone microstructural deterioration. Early identification of osteoporosis and implementation of preventive interventions remain critical for reducing fracture risk and disease burden. Identifying plasma biomarkers reflecting metabolic alterations related to OP may facilitate early detection and risk assessment.
methodsUntargeted metabolomics and lipidomics profiling based on ultra-performance liquid chromatography-mass spectrometry (UHPLC-MS) was performed in a discovery cohort comprising 75 patients with OP and 140 healthy controls. Differential features were identified using multivariate statistical analysis (PCA, OPLS-DA), and FDR-adjusted univariate analysis. Multivariable logistic regression and LASSO-regularized logistic regression was employed, with age and sex incorporated as mandatory covariates to identify independent lipid predictors. A Random Forest (RF) model was further evaluated in an independent validation cohort consisting of 20 OP patients and 42 healthy controls.
resultSixty-one differential metabolites were identified, primarily enriched in lipid metabolism pathways. Further targeted lipidomics identified four diagnostic lipid biomarkers, including LPA(16:0), LPI(16:0), LPI(18:0), and LPI(20:0). Following covariate adjustment for age and sex, key lipid species remained independently associated with OP. The RF-based diagnostic model maintained robust performance in the validation cohort, yielding an AUC of 0.916 (95% CI: 0.842-0.990), with high sensitivity and specificity.
conclusionsLPA(16:0), LPI(16:0), LPI(18:0), and LPI(20:0) in plasma were negatively correlated with the T value of bone mineral density. These associations persisted after stringent adjustment for age and sex, suggesting that lysophospholipid dysregulation is an independent metabolic hallmark of OP. The multi-metabolites model based on four biomarkers showed promising predictive performance for OP and may provide a potential tool for early risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.